{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+2-+Dose+Expansion&page=4", "query": { "intervention": "Arm 2- Dose Expansion", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 405, "total_pages": 41, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+2-+Dose+Expansion&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+2-+Dose+Expansion&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T11:31:10.423Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06996782", "title": "A Platform Study in Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced or Metastatic Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152, "start_date": "2025-11-24", "completion_date": "2029-02-23", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-14T11:31:10.423Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Santa Rosa, California • Jacksonville, Florida + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06996782" }, { "nct_id": "NCT07206056", "title": "An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Progressive Metastatic Castrate Resistant Prostate Cancer" ], "interventions": [ { "name": "Tulmimetostat DL1 QD", "type": "DRUG" }, { "name": "Tulmimetostat DL2 QD", "type": "DRUG" }, { "name": "Tulmimetostat DL3 QD", "type": "DRUG" }, { "name": "Tulmimetostat Doses 1 or 2 QD", "type": "DRUG" }, { "name": "Tulmimetostat RP2D QD", "type": "DRUG" }, { "name": "JSB462 Dose 1 QD", "type": "DRUG" }, { "name": "JSB462 Dose 2 QD", "type": "DRUG" }, { "name": "JSB462 QD", "type": "DRUG" }, { "name": "Standard of Care (SoC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 188, "start_date": "2025-10-15", "completion_date": "2030-12-01", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-14T11:31:10.423Z", "location_count": 8, "location_summary": "Denver, Colorado • Jacksonville, Florida • Atlanta, Georgia + 5 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07206056" }, { "nct_id": "NCT02406742", "title": "A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia, Lymphocytic, Chronic, B-Cell" ], "interventions": [ { "name": "CC-122", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 47, "start_date": "2015-07-27", "completion_date": "2020-07-07", "has_results": true, "last_update_posted_date": "2021-09-20", "last_synced_at": "2026-10-14T11:31:10.423Z", "location_count": 8, "location_summary": "La Jolla, California • Boston, Massachusetts • Hackensack, New Jersey + 5 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02406742" }, { "nct_id": "NCT04249843", "title": "Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "B-Raf Mutation-Related Tumors" ], "interventions": [ { "name": "Brimarafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MapKure, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 109, "start_date": "2020-02-10", "completion_date": "2025-08-08", "has_results": true, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-10-14T11:31:10.423Z", "location_count": 5, "location_summary": "Beverly Hills, California • Boston, Massachusetts • New York, New York + 2 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04249843" }, { "nct_id": "NCT03116113", "title": "A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "X-Linked Retinitis Pigmentosa" ], "interventions": [ { "name": "BIIB112", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": null, "sex": "MALE", "summary": "10 Years and older · Male only" }, "enrollment_count": 50, "start_date": "2017-03-08", "completion_date": "2020-11-18", "has_results": true, "last_update_posted_date": "2024-01-18", "last_synced_at": "2026-10-14T11:31:10.423Z", "location_count": 5, "location_summary": "Gainesville, Florida • Miami, Florida • Portland, Oregon + 2 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Portland", "state": "Oregon" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03116113" }, { "nct_id": "NCT02988960", "title": "A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors Cancer" ], "interventions": [ { "name": "ABBV-927", "type": "DRUG" }, { "name": "ABBV-181", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 163, "start_date": "2017-02-22", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2026-01-09", "last_synced_at": "2026-10-14T11:31:10.423Z", "location_count": 7, "location_summary": "Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02988960" }, { "nct_id": "NCT01380756", "title": "Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Hematologic Malignancies", "Leukemia", "Myeloid Leukemia" ], "interventions": [ { "name": "Arm 1- Dose Escalation", "type": "DRUG" }, { "name": "Arm 2- Dose Expansion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2011-10-04", "completion_date": "2014-09-04", "has_results": false, "last_update_posted_date": "2017-11-06", "last_synced_at": "2026-10-14T11:31:10.423Z", "location_count": 3, "location_summary": "Stony Brook, New York • Cleveland, Ohio • Houston, Texas", "locations": [ { "city": "Stony Brook", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01380756" }, { "nct_id": "NCT02266745", "title": "A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "CRPC", "mCRPC", "Metastatic Castrate-resistant Prostate Cancer", "PT-112", "Prostatic Neoplasms", "Genital Neoplasms, Male", "Urogenital Neoplasms", "Neoplasms by Site" ], "interventions": [ { "name": "PT-112 Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Promontory Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 109, "start_date": "2014-07", "completion_date": "2025-04-01", "has_results": false, "last_update_posted_date": "2024-04-05", "last_synced_at": "2026-10-14T11:31:10.423Z", "location_count": 17, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Duarte, California + 14 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02266745" }, { "nct_id": "NCT06255028", "title": "A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Systemic Lupus Erythematosus", "Lupus Nephritis", "Idiopathic Inflammatory Myopathies", "Diffuse Cutaneous Systemic Sclerosis" ], "interventions": [ { "name": "CNTY-101", "type": "BIOLOGICAL" }, { "name": "IL-2", "type": "BIOLOGICAL" }, { "name": "Lymphodepleting Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Century Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "17 Years", "maximum_age": null, "sex": "ALL", "summary": "17 Years and older" }, "enrollment_count": 6, "start_date": "2025-02-06", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2026-01-08", "last_synced_at": "2026-10-14T11:31:10.423Z", "location_count": 6, "location_summary": "Los Angeles, California • Sacramento, California • Chicago, Illinois + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Houston", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06255028" }, { "nct_id": "NCT05091424", "title": "A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Mosunetuzumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 332, "start_date": "2022-03-07", "completion_date": "2032-02-10", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-14T11:31:10.423Z", "location_count": 5, "location_summary": "Rochester, Minnesota • New York, New York • Columbus, Ohio + 2 more", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05091424" } ] }